
Please try another search
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Name | Age | Since | Title |
---|---|---|---|
Yu-Hsin Lin | 44 | 2018 | Chairman of the Board of Directors & CEO |
Hao-Yuan Chuang | 39 | 2020 | CFO & Director |
Wan-Shan Chen | 38 | 2021 | Director |
Yuan Lu | 47 | 2022 | Independent Director |
Gary C. Biddle | 72 | 2022 | Independent Director |
John M. Longo | 55 | 2022 | Independent Director |
Xiao-Hui Chen | 37 | 2025 | Director |
Frank G. Holz | - | - | Member of Ophthalmology Clinical Advisory Board |
Quan Dong Nguyen | - | - | Member of Ophthalmology Clinical Advisory Board |
Robyn Guymer | - | - | Member of Ophthalmology Clinical Advisory Board |
Michel Michaelides | - | - | Member of Ophthalmology Clinical Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review